Treatment strategy for rheumatoid arthritis with lung scarring
Treatments studied
Part of Immune system & allergy, Lungs & breathing clinical trials.
This study tests a treatment plan for people who have rheumatoid arthritis and interstitial lung disease (scarring in the lungs). The goal is to find the best way to treat both conditions together and slow lung damage.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have been diagnosed with rheumatoid arthritis (RA) based on standard clinical criteria
- Imaging of your lungs shows scarring or damage (at least 20% of lung tissue affected)
- Your lung function tests show reduced capacity (FVC <80% or DLCO <70% of predicted)
- If you take steroids, you must be on a stable low dose (≤10 mg prednisone daily) for at least 4 weeks
- If you take other RA medications, they must be stable for at least 4 weeks before starting
- You are willing to attend all study visits and follow-up appointments
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial is for people with rheumatoid arthritis (RA) who are at risk for developing interstitial lung disease, which is scarring in the lungs. It aims to better understand why this happens and how to help prevent or manage it.
This study tests whether a combination of two drugs, nintedanib and tocilizumab, can help people with systemic sclerosis (a condition that causes skin and organ hardening) who also have lung scarring (interstitial lung disease). The goal is to find a treatment that can slow down the disease.
This trial studies whether rituximab can slow worsening lung scarring (interstitial lung disease) when there is an inflammatory component. You would get rituximab or a placebo (inactive treatment) in a blinded, randomized design to compare safety and effectiveness.
This study is looking at people with rheumatoid arthritis (RA) who also have interstitial lung disease (ILD), a condition that causes scarring in the lungs. It aims to understand how the disease changes over time by using imaging and blood tests, without providing any new treatments right now.
This study looks for early lung scarring in people who have rheumatoid arthritis. It may help find a serious lung condition earlier so doctors can watch or treat it sooner.
This study helps doctors identify early signs of lung scarring (fibrosis) in patients with autoimmune diseases like scleroderma, rheumatoid arthritis, and Sjögren's syndrome. By catching this early, researchers hope to better understand and treat these complications.
Hear when a new Rheumatoid Arthritis-Associated Interstitial Lung Disease trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.